| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Elderly, Children, Adult |
| State: | Powder |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Docetaxel |
| Assay | 99% |
| Test Method | HPLC |
| Appearance | White Crystalline Powder |
| CAS | 114977-28-5 |
| Molecular Formula | C43H53NO14 |
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel has an approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline-based chemotherapy and failed to stop cancer progression or relapsed.
Administered as a one-hour infusion every three weeks generally over a ten cycle course, docetaxel is considered better than doxorubicin, paclitaxel and fluorouracil as a cytotoxic antimicrotubule agent.
1.It is a clinically well established anti mitotic chemotherapy medication (that is, it interferes with cell division).
2.It is used mainly for the treatment of breast, ovarian, and non-small cell lung cancer.
3.It has an approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline based chemotherapy and failed to stop cancer progression or relapsed. An European approval docetaxel for use in hormone-refractory prostate cancer.
4.It is considered better than doxorubicin, paclitaxel and fluorouracil as a cytotoxic antimicrotubule.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}